ProShare Advisors
PTGX icon

ProShare Advisors’s Protagonist Therapeutics PTGX Stock Holding History

ProShare Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Sell
10,878
-1,040
-9% -$109K ﹤0.01% 737
2026
Q1 		$1.26M Sell
11,918
-2,166
-15% -$192K ﹤0.01% 750
2025
Q4 		$1.23M Buy
14,084
+897
+7% +$73.4K ﹤0.01% 773
2025
Q3 		$876K Sell
13,187
-2,189
-14% -$124K ﹤0.01% 852
2025
Q2 		$850K Sell
15,376
-1,382
-8% -$66.3K ﹤0.01% 877
2025
Q1 		$810K Sell
16,758
-3,699
-18% -$155K ﹤0.01% 872
2024
Q4 		$790K Buy
20,457
+4,776
+30% +$208K ﹤0.01% 1022
2024
Q3 		$706K Buy
15,681
+4,411
+39% +$178K ﹤0.01% 936
2024
Q2 		$391K Sell
11,270
-3,075
-21% -$90.1K ﹤0.01% 1119
2024
Q1 		$415K Buy
14,345
+1,206
+9% +$32.8K ﹤0.01% 1199
2023
Q4 		$301K Buy
13,139
+1,957
+18% +$34.2K ﹤0.01% 1374
2023
Q3 		$187K Buy
11,182
+427
+4% +$8.29K ﹤0.01% 1494
2023
Q2 		$297K Buy
10,755
+1,869
+21% +$46.8K ﹤0.01% 1277
2023
Q1 		$204K Buy
+8,886
New +$149K ﹤0.01% 1435
2022
Q2 		– Sell
-13,399
Closed -$317K – 2051
2022
Q1 		$317K Sell
13,399
-3,090
-19% -$87.1K ﹤0.01% 1588
2021
Q4 		$564K Buy
16,489
+597
+4% +$18.9K ﹤0.01% 1363
2021
Q3 		$282K Sell
15,892
-2,729
-15% -$116K ﹤0.01% 1593
2021
Q2 		$836K Buy
18,621
+3,254
+21% +$107K ﹤0.01% 1140
2021
Q1 		$398K Buy
15,367
+2,492
+19% +$63.1K ﹤0.01% 1609
2020
Q4 		$260K Buy
+12,875
New +$277K ﹤0.01% 1706

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ProShare Advisors's PTGX Position: Q2 2026 in Review

ProShare Advisors reduced its Protagonist Therapeutics (PTGX) stake by 8.7% in Q2 2026, selling an estimated $109K and leaving 10,878 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #737.

ProShare Advisors first reported a position in PTGX in Q4 2020 and has held it in 20 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • ProShare Advisors held 10,878 shares of Protagonist Therapeutics worth $1.33M as of Q2 2026.
  • ProShare Advisors sold 1,040 Protagonist Therapeutics shares in Q2 2026, an estimated $109K.
  • Protagonist Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #737 holding.
  • ProShare Advisors first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.